Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01525823 | Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin | PHASE1 | COMPLETED | 26 | — | — | Feb 1, 2012 | Apr 1, 2012 | Jun 14, 2012 | 1 | Australia |
| Arm | Type | Description |
|---|---|---|
| BMS-754807 + Metformin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-754807 (IGR-IR/IR Inhibitor) | DRUG | Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17 |
| Metformin | DRUG | Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily |
Inclusion Criteria: * Healthy male and female subjects ages 18 to 55 determined with no clinically significant deviation from normal medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory * Women who are not of childbearing potential Exclusion Criteria: * Eviden...